The study follows the successful first-in-human ICVAX Phase 1 clinical trial that showed exceptional safety and promising immunogenicity profiles.³ The vaccine represents a significant step towards achieving virological control by ICVAX without antiretroviral therapy and ultimately becoming a functional cure of human immunodeficiency virus (HIV)/AIDS. Immuno Cure is investigating the potential for the Tropis ID system to improve the DNA vaccine performance and patient’s clinical experience.

Intradermal delivery is expected to help elicit long-lived and cross-reactive immune responses. The Tropis system easily leverages the rich network of dendritic cells, macrophages and T cells in the dermal layer and can provide a more potent and broader immunogenic response than vaccinating into the muscle.¹ Tropis is commercially scaled, has been used for over 12 million injections, and is the first and only needle-free ID delivery technology to achieve World Health Organization (WHO) prequalification.

Dr. Xia Jin MD PhD, CEO of Immuno Cure, said, “At Immuno Cure, our mission is to advance transformative therapies for infectious diseases and cancer. We are excited to partner with PharmaJet and leverage their Tropis Needle-free Injection System on our HIV therapeutic DNA vaccine program. We value innovative approaches that could enhance patient experience and vaccine performance.”

“This agreement adds to our portfolio of global development partnerships with innovative oncology and infectious disease developers. Our partners are joining our call to challenge antiquated IM administration methods in favor of ID delivery based on the growing body of evidence⁴ demonstrating improved immune responses and safety profiles,” said Dan Mallon, Senior Vice President Corporate Development, PharmaJet. “PharmaJet’s needle-free technology is safe and well-tolerated and has shown to enable immune responses that are robust and durable.”

Refer to Instructions for Use to ensure safe injections and to review risks.